



01/02/02

Docket No. JBP-518

TECH CENTER 1600/2900

RECEIVED
JAN 09 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Seiberg, et al.

Serial No. : 09/698,454

Art Unit: 1616

Filed : October 27, 2000

Examiner: M. Lamm

For : SOY DEPIGMENTING AND SKIN CARE COMPOSITIONS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as Express Mail in an envelope addressed
to: Commissioner For Patents, Washington, D.C. 20231 on

December 27, 2001

(Date of Deposit)

Andrea L. Colby

(Name of applicant, assignee, or Registered Representative)

Andrea L. Colby

(Signature)

December 27, 2001

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

01/09/2002 55ANDARA 000000001 100750 09698454

180.00 CH

01 FC:126

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e)
(attached); or

☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e)
(attached); or
- ☒ Please charge Deposit Account No. 10-
0750/JBP518/ALC the fee of \$180.00 as set forth
in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☒ In view of the voluminous nature of references, all are not available at this moment. References marked with an asterick (*) and highlighted in yellow will arrive under separate cover.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

RECEIVED

JAN 09 2002

TECH CENTER 1600/2900

☐ There are no listed references which are not in the English language.


☒ The relevance of those listed references which are not in the English language is as follows: Japanese

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☒ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JBP518/ALC. This form is submitted in triplicate.

Respectfully submitted,



Andrea L. Colby
Reg. No. 30194
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2792
DATED:



01/02/02

161/68

DOCKET NO. JBP 0518

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 09 2002

TECH CENTER 1600/2900

Applicant: Seiberg, et al.

For : SOY DEPIGMENTING AND SKIN CARE COMPOSITIONS

Express Mail Certificate

"Express Mail" mailing number: EL691442792US AND EL691442801US

Date of Deposit: December 27, 2001


I hereby certify that this Information Disclosure Statement, two
boxes of references and postcard, is being deposited with the
United States Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR 1.10 on the date indicated above
and is addressed to the Commissioner for Patents, Washington,
D.C. 20231.

A Combined Declaration and Power of Attorney will be submitted
to the United States Patent and Trademark Office upon receipt of
the U.S. Serial Number for this patent application.

Arthur Rausch

(Typed or printed name of person mailing paper or fee)

Arthur J. Rausch
(Signature of person mailing paper or fee)



#5

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Subsidiary Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
WJ		4,151,304		Evans	4/24/79	TECH CENTER 1600/2900
		4,223,018		Belle	9/16/80	
		4,272,544		Cella	6/9/81	
		4,278,570		Flom	7/14/81	
		4,333,927		Ofuchi	6/8/82	
		4,368,187		Flom	1/11/83	
		4,370,315		Greff	1/25/83	
		4,382,960		Flom	5/10/83	
		4,386,067		Guillon	5/31/83	
		4,427,670		Ofuchi	1/24/84	
		4,462,981		Smith	7/21/84	
		4,486,448		Ser	12/4/84	
		4,488,564		Grollier	12/18/84	
		4,515,778		Kastell	5/7/85	
		4,524,067		Arichi	6/18/85	
		4,537,782		Millet	8/27/85	
		4,550,035		Smith	10/29/85	
		4,578,267		Salamone	3/25/86	
		4,604,281		Deckner	8/5/86	
		4,612,192		Scheuffgen	9/16/86	
		4,690,821		Smith	9/1/87	
		4,707,293		Ferro	12/17/87	
		4,760,096		Sakai	7/26/88	
		4,793,991		Slimak	12/27/88	
		4,847,267		Deckner	7/11/89	
		4,851,214		Walters	7/25/89	
		4,859,458		Salamone	8/22/89	
		4,871,530		Grollier	10/3/89	

RECEIVED

JAN 09 2002

1/17/05

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 18


Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
HLL		4,895,839		Bombardelli	1/23/90	
		4,943,462		Komerska	7/24/90	
Ull		4,960,588		Hoshowski	10/2/90	JTECH CENTER 1600/2900
		4,970,216		Deckner	11/13/90	
		5,002,761		Mueller	3/26/91	
		5,032,382		Crollier	7/16/91	
		5,032,400		Wiersum	7/16/91	
		5,077,038		Hofmann	12/31/91	
		5,077,040		Bergmann	12/31/91	
		5,104,655		Bombardelli	4/14/92	
		5,110,603		Rau	5/5/92	
		5,116,605		Alt	5/26/92	
		5,118,671		Bombardelli	6/2/92	
		5,147,859		Bombardelli	9/15/92	
		5,166,139		Bombardelli	11/24/92	
		5,171,577		Griat	12/15/92	
		5,188,823		Shapiro	2/23/93	
		5,192,332		Lang	3/9/93	
		5,194,252		Hofmann	3/16/93	
		5,229,104		Sottery	7/20/93	
		5,231,090		Hsia	7/27/93	
		5,248,495		Patterson	9/28/93	
		5,254,331		Mausner	10/19/93	
		5,270,042		Whitham	12/14/93	
		5,310,734		Losch	5/10/94	
		5,322,839		Voegeli	6/21/94	
		5,352,443		Kubo	10/4/94	

RECEIVED

JAN 6 5 2002



1/17/02

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 3 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
UL		5,364,886		Loliger	11/15/94	
		5,393,519		Dowell	2/28/95	
UL		5,397,497		Jakobson	3/14/95	
		5,407,675		Etemad-Moghadam	4/18/95	
		5,411,742		Sebag	5/2/95	
		5,427,814		Loliger	6/27/95	
		5,428,026		Colarow	6/27/95	
		5,438,044		Losch	8/1/95	
		5,439,672		Zabotto	8/8/95	
		5,446,605		Umehara	8/29/95	
		5,498,420		Mentrup Edgar	3/12/96	
		5,547,661		Sun	8/20/96	
		5,567,420		McEleney	10/22/96	
		5,578,297		Mellul	11/26/96	
		5,928,889		Bakich	7/27/99	
		5,985,338		Suh	11/16/99	
		5,985,809		Frankenback	11/16/99	
		5,990,291		Waggle	11/23/99	
		6,004,915		Elliott	12/21/99	
		6,013,250		Cannell	1/11/00	
		6,013,255		Edens	1/11/00	
		6,017,893		Segelman	1/25/00	
		6,019,962		Rabe	2/1/00	
		6,030,931		Vinski	2/29/00	
		6,033,680		Dixon	3/7/00	
		6,045,779		Mueller	4/4/00	
		6,048,520		Hoshowski	4/11/00	
		6,063,398		Gueret	5/16/00	



1/17/05

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 4 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
WJ		5,569,663		Ribier	10/29/96	<p style="writing-mode: vertical-rl; transform: rotate(180deg);"> RECEIVED JAN 09 2002 TECH CENTER 1600/2900 </p>
		5,589,181		Bencsits	12/31/96	
		5,601,833		Roboer	2/11/97	
		5,603,949		Meybeck	2/18/97	
		5,607,666		Masson	3/4/97	
		5,607,692		Ribier	3/4/97	
		5,614,180		Chung	3/25/97	
		5,618,522		Kaleta	4/8/97	
		5,620,692		Potter	4/15/97	
		5,629,015		Ribier	5/13/97	
		5,631,318		Ito	5/20/97	
		5,635,165		Panitch	6/3/97	
		5,637,316		Ribier	6/10/97	
		5,641,509		Gross	6/24/97	
		5,643,583		Voultoury	7/1/97	
		5,643,601		Gross	7/1/97	
		5,643,587		Scancarella	7/1/97	
		5,650,166		Ribier	7/22/97	
		5,653,988		Gerber	8/5/97	
		5,660,853		Hansenne-Richoux	8/26/97	
		5,674,511		Kacher	10/7/97	
		5,676,935		Mellui	10/14/97	
		5,676,956		Duffy	10/14/97	
		5,679,374		Fanchon	10/21/97	
		5,683,683		Scafidi	11/4/97	
		5,686,102		Gross	11/11/97	
		5,723,148		Love	3/3/98	



11/7/01

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet 5 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
ul		5,762,916		Ansmann	6/9/98	
		5,741,496		Khaiat	4/21/98	
ul		5,766,628		Nurnberg	6/16/98	
		5,804,216		Terren	9/8/98	
		5,833,965		Sun	11/10/98	
		5,807,545		Coffindaffer	9/15/98	
		5,834,013		Ribier	11/10/98	
		5,863,546		Swinehart	1/26/99	
		5,885,593		Epstein	3/23/99	
		5,885,596		Parab	3/23/99	
		5,885,600		Blum	3/23/99	
		5,885,617		Jordan	3/23/99	
		5,885,948		Glenn	3/23/99	
		5,908,618		Lorant	6/1/99	
		5,916,577		Golz	6/29/99	
		5,928,658		Kishida	7/27/99	
		5,942,479		Frankenback	8/24/99	
		5,945,095		Mougin	8/31/99	
		5,945,109		Schmidt	8/31/99	
		5,958,387		Bara	9/28/99	
		5,962,015		Delrieu	10/5/99	
		5,965,153		Allen	10/12/99	
		5,981,450		Fabry	11/9/99	
		4,885,169		Gazzani	12/05/89	
		4,906,457		Ryan	03/06/90	
		5,217,717		Kennedy	06/08/93	
		5,306,444		Kitamura	04/26/94	
		4,279,930		Hall	9/14/79	
		5,643,587		Scancarella	2/15/96	

[Signature] 1/17/01



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 6 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
Ull		5,523,308		Costanzo	06/04/96	
		5,614,215		Ribier	03/25/97	
Ull		5,622,690		Potter	04/22/97	
		5,753,612		Mitrani	05/19/98	
		5,755,814		Berg	05/26/98	
		5,824,702		Wei	10/20/98	
		5,871,743		Chajuss	02/16/99	
		5,928,654		Duranton	07/27/99	
		5,961,980		Kennedy	10/05/99	
		4,824,662		Hofmann	4/25/89	
		5,043,323		Bombardelli	8/27/91	
		5,571,503		Mausner	11/5/96	
		5,824,702		Wei	10/20/98	
		5,928,654		Duranton	7/27/99	
		3,755,560		Dickert	8/28/73	
		4,254,105		Fukuda	3/3/81	
		4,421,769		Dixon	12/20/83	
		4,960,764		Figueroa	10/2/90	
		5,260,065		Mathur	11/9/93	
		6,051,602		Bissett	4/18/00	
		3,625,976		Theimer	12/7/71	
		4,190,671		Vanstone	2/26/80	
		4,219,569		Glenn	8/26/80	
		4,297,348		Frazier	10/27/81	
		4,331,692		Drevici	5/25/82	
		4,439,418		Moller	3/27/84	
		4,584,190		Tejima	4/22/86	
		4,834,076		Millet	5/30/89	
		4,867,964		Forestier	9/19/89	



[Signature] 1/17/01

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

-(use as many sheets as necessary)-

Sheet 7 of 18

Application Number

09/698,454

Filing Date

October 27, 2000

First Named Inventor

Seiberg, et al.

Group Art Unit

1616

Examiner Name

M. Lamm

Attorney Docket Number

JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
ULL		5,179,091		Lesieur	1/12/93	
		5,276,058		Satoh	1/4/94	
ULL		5,362,494		Zysman	11/8/94	
		5,443,839		Meybeck	8/22/95	
		5,443,840		Morancais	8/22/95	
		5,466,452		Whittle	11/14/95	
		5,539,129		Zysman	7/23/96	
		5,545,399		Lee	8/13/96	
		5,626,868		Morancais	5/6/97	
		5,643,587		Scancarella	7/1/97	
		5,665,367		Burger	9/9/97	
		5,681,852		Bissett	10/28/97	
		5,880,314		Shinomiya	3/9/99	
		4,439,418		Moller	3/27/84	
		6,093,411		Bissett	7/25/00	
		5,952,373		Lanzendorfer	9/14/99	
		5,639,785		Kung	6/17/97	
		4,437,895		Koulbanis	3/20/84	
		6,060,070		Gorbach	5/9/00	
		5,605,894		Blank	2/25/97	
		5,776,917		Blank	7/7/98	
		5,780,459		Blank	7/14/98	
		5,786,345		Blank	7/28/98	
		5,789,396		Blank	8/4/98	
		5,869,470		Blank	2/9/99	
		5,595,984		Blank	1/21/97	
		5,597,814		Blank	1/28/97	
		5,616,572		Blank	4/1/97	
		5,629,301		Blank	5/13/97	

1/17/01

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 8 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
u		5,652,230		Blank	7/29/97	
		5,691,327		Blank	11/25/97	
u		5,780,456		Blank	7/14/98	
		5,780,458		Blank	7/14/98	
		5,786,346		Blank	7/28/98	
		5,795,879		Blank	8/18/98	
		5,801,163		Blank	9/1/98	
		5,840,717		Blank	11/24/98	
		5,843,926		Blank	12/1/98	
		5,962,441		Blank	10/5/99	
		6,183,761		Bissett	2/6/01	
		6,180,662		Lanzendorfer	1/30/01	
		6,054,137		Breton	4/25/00	
		4,885,169		Gazzani	12/5/89	
		5,755,814		Berg	5/26/98	



[Handwritten signature] 1/17/05

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document Mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
		Office ³	Number ⁴	KindCode ⁵				
u		WO 98/08503			Novogen Research Pty. Ltd.	3/5/98		
		WO 98/49153			Novogen Inc.	11/5/98		
u		WO 99/36050			Novogen Research Pty. Ltd.	7/22/99		
		JP 3-127713			Sansho Pharmaceutical Co. Ltd.	5/30/91		X
		JP 4-169514			Shiseido Co. Ltd.	6/17/92		X
		JP 5-320024			Dowa Mining Co. Ltd.	12/3/93		X
		JP 58-225003			Ichimaru Farkos Co. Ltd.	12/27/83		
		JP 63-68512			Awase Cosfa Co. Ltd.	3/28/88		X
		WO 91/07166			Washington State University	05/30/1991		X
		WO 96/19483			Biochem Pharma Inc.	06/27/1996		
		WO 96/19491			Biochem Pharma Inc.	06/27/1996		
		WO 96/30035			Molecumetrics Ltd.	10/03/1996		
		WO 96/30396			Molecumetrics Ltd.	10/03/1996		
		WO 96/37497			Biochem Pharma Inc.	11/28/1996		
		WO 97/35998			Trustees of Boston University	10/02/1997		
		WO 98/05333			Molecumetrics Ltd.	02/12/1998		
		WO 98/09987			Biochem Pharma Inc.	03/12/1998		
		WO 99/24003			Procter & Gamble Co.	05/20/1999		
		RU 2066992			Procter & Gamble Co.	09/27/1996		
		JP 3-127713			Tachibana	10/09/1989		X
		JP 4-169514			Kitamura	11/01/90		X
		JP 5-320024			Dowa Mining Company, Ltd.	05/21/1992		X
		JP 5-320061			Soken Co.	05/19/91		X
		JP 8-20597			Meiji Pharmaceutical Company, Ltd	07/07/1994		X
		JP 58-225003			Yoshihiro Chikamatsu	06/23/1982		X
		JP 63-68512			Yoshitaka Ujic	09/09/1986		X
								X

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document Mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
ucl			EP0421021		Mucos	6/10/89		
			WO9624371		Phairson Medical Inc.	8/15/96		
			PCT WO00/15188		Sederna	3/23/00		
			PCT WO96/31194		J&J Consumer Products Inc.	10/10/96		
			PCT/US 97/11033		Nord-Beton GMBH	3/27/97		
			EP 273,202		Henkel	6/21/95		
			EP 0707851		Fockerman	4/24/96		
			EP0774249		Unilever	5/21/97		
			EP 0811595		Mitsui	12/10/97		
			JP 63-96120		Matsuura Pharmaceutical Co.	4/27/88		X
ucl late ucl			JP 63-316711		Nonogawa Shoji	6/17/87		X
			JP 5 114806		?	?		
			JP 5-213729		Kao Corporation	8/24/93		X
			JP 5-246932		Nippon High Box Co.	9/24/93		X
			EP 0473502		Shiseido Co. Ltd.	3/4/92		
			WO 00/69408 A1		Proctor & Gamble Co.	11/23/00		
			WO 00/69407 A1		Proctor & Gamble Co.	11/23/00		
			WO 00/69406 A1		Proctor & Gamble Co.	11/23/00		
			WO 00/69404 A1		Proctor & Gamble Co.	11/23/00		
			WO 98/02134		J&J Consumer Products Inc.	1/22/98		

Examiner
SignatureDate
Considered

1/17/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 11 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document Mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
		Office ³	Number ⁴	KindCode ⁵				
u	u	WO 00/62745	A3		Procter & Gamble	10/26/00		
		WO 00/62744	A3		Procter & Gamble	10/26/00		
		WO 00/62743	A3		Procter & Gamble	10/26/00		
		WO 00/62741	A2		Procter & Gamble	10/26/00		
		WO 00/62740	A2		Procter & Gamble	10/26/00		
		WO 00/51554	A3		Johns Hopkins University	9/8/00		

Examiner Signature		Date Considered	1/17/01
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-------------------------	--------------------------	--	----------------

u The Complete Amino Acid Sequence of Rice Bran Trypsin Inhibitor: J. Biochem 102, 2970-306 (1987).

Wheat Germ-Trypsin-Inhibitors. Isolation and Structural Characterization of Single-Headed and Double-Headed Inhibitors of the Bowman-Birk Type: J. Biochem 100, 975-983 (1986).

Aqueous Ethanol Extraction of Soybean Trypsin Inhibitors and Characterization of a Calcium-Sensitive: Keshun Liu, Journal of Food Biochemistry 15 (1991) 159-168.

Amino Acid Sequence and Secondary Structural Analysis of the Corn Inhibitor of Trypsin and Activated Hageman Factor, Walter C. Mahoney: Journal of Biological Chemistry, Vol 259, No. 13 July 10, 1984, 8412-8416.

Trypsin Inhibitor Polymorphism: Multigene Family Expression and Posttranslational Modification, Laurence Quillien: Journal of Protein Chemistry, Vol. 16, No. 3 (1997) 195-203.

Inhibition of Serine Proteases of the Blood Coagulation System by Squash Family Protease Inhibitors, Kaeko Hayashi: J. Biochem. 116, 1013-1018 (1994).

Primary Structure of a Kunitz-Type Trypsin Inhibitor From Enterolobium Contortisiliquum Seeds, I.F.C. Batista: Phytochemistry Vol 41, No. 4, (1996) 1017-1022.

Amino Acid Sequences of Double-headed Proteinase Inhibitors from the Seeds of Canavalia lineata, Shigeyuki Terada: Biosci. Biotech. Biochem. Vol 58, (2) 376-379 (1994).

The biochemistry and nutrition group: 30 years of research in a developing country, Abraham Levy Benshimol: Archivos Latinoamericanos De Nutricion, Vol 44, No. 4-S, pp 6-S-9-S (1994).

High-Performance Liquid Chromatographic Analysis of Phytoestrogens in Soy Protein Preparations with Ultraviolet Electrochemical and Thermospray Mass spectrometric Detection, K.D. R. Setchell: Journal of Chromatography 386 (1987) 315-323.

Interaction of Proteases with Legume Seed Inhibitors. Molecular features, Dinah S. deSeidl: Archivos Latinoamericanos de Nutricion, Vol 44 No. 4-S (1994) 21-S-25-S.

Soy Intake and Cancer Risk: A Review of the InVitro and InVivo Data, Mark J. Messina: Nutricion and Cancer Vol. 21, No. 2, (1994) 113-131.

The Use of Thermospray Liquid Chromatography/Tandem Mass spectrometry for the Class Identification and Structural Verification of Phytoestrogens in Soy Protein Preparations, Robert J. Barbuch: Biomedical and Environmental Mass Spectrometry, Vol. 18, (1989) 973-977.


Defining Food Components as New Nutrients, Suzanne Hendrick: American Institute of Nutrition (1994) 1789S-1792S.

u Relevance of Multiple Soybean Trypsin Inhibitor Forms to Nutritional Quality, Anna L. Tan-Wilson, Department of Biological Sciences, State University of New York at Binghamton, 391-411

u Nutrition Communique Soy: Just a Hill of Beans? Clare M. Hasler: Journal of women's Health, Vol 7, No. 5 (1998) 519-523.

u Protein Proteinase inhibitors in legume seeds - Overview, Yehudith Birk: Archivos Latinoamericanos de Nutricion, Vol. 44, No. 4-S (1994) 26-S-30-S.

u The Effect of a Drug-delivery System Consisting of Soybean Phosphatidyl Choline and Medium-chain Monoacylglycerol on the Intestinal Permeability of Hexarelin in the Rat, Urban Fagerholm: J. Pharm. Pharmacol (1998) 50: 467-473.

Examiner Signature		Date Considered	1/17/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
----------------------	-----------------------	--	----------------

u u u A Serine Protease From Suspension-Cultured soybean Cells, Ze-Jian Guo: Phytochemistry, Vol. 47, No. 4 (1998) 547-553.

u u u Trypsin-Inhibitor Activity in Commercial Soybean Products in Japan, Yuko Miyagi: J. Nutr. Sci. Vitaminol (1997) Vol. 43: 575-580.

u u u Soy-derived protease inhibitors treat cancer and inflammation, Louis J. Scott: Windhover Information Inc. (1998).

u u u Crystal Structure of the Complex of Porcine Pancreatic Trypsin with Kunitz-Type Soybean Trypsin Inhibitor, Hyun K. Song: www.bmsc.wahing...ts/abstracts/S0081.html

u u u Two Groups of Protease Inhibitors Functionally Active in Buckwheat Seeds, Yakov Dunaevsky: seba.shinshu-uac.jp/contents/105.html

u u u Isolation and Properties of Anionic Protease Inhibitors from Buckwheat Seeds, Y.E. Dunaevsky: Biochemistry and Molecular Biology International, Vol. 40, No.1, (1996) 199-208.

u u u Effect of Heat Treatments on Trypsin/Chymotrypsin Inhibitor Activity of Red Gram (Cajanus Cajan L.), V.H. Mulimani: Plant Foods for Human Nutrition, Vol. 46, No. 2, ((1994) 103-107.

u u u Effects of heat treatment and germination on trypsin and chymotrypsin inhibitory activities in sorghum (Sorghum bicolor (L.) Moench) seeds, V.H. Mulimani: Plant Foods for Human Nutrition, Vol. 44, No. 3 (1993) 221-226.

u u u The Joy of Soy: www.wheat-grass.com/851_oral_liquid.shtml

u u u Concerns Regarding Soybeans: www.rheumatic.org/soy.htm

u u u Evaluation of the Effects of Hair Re-growth substances on Elongation of Anagen Period and Blockade of Anagen-Catagen Transformation, Kazuto Hamada: J. Soc. Cosmet. Chem. Japan, Vol 31, No. 4 (1997) 1-3.

u u u Current problem of research on hair growth mechanisms and hair growth promoters, Hideki Ogawa: Fragrance Journal (1985) Vol. 5, 1-5.

u u u Brochure on Lipoxylase Code 411784, April 1999.

u u u Brochure for Anti-regrowth effect of hair: December 22, 1998.

u u u Phytosterol Content of Processed Soybean Products, P.A. Murphy: Food Technology, Vol 1, 60-64 (1982).

u u u Soy Therapy, www.wiseessentials.com/soytherapy.html (4-13-2000)


u u u "CaspACE Assay System, Colorimetric," Product Improvements, Neural Notes Volume V, Issue 1 1999, p.13

u u u "RQ1 RNase Free DNase, Promega," Technical Bulletin No. 518, pp. 1-4, Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711-5399

u u u "Invitrogen Life Technologies, ThermoScript RNase H-Reverse Transcriptase," www.invitrogen.com/content.cfm

u u u PIOTR CHOMCZYNSKI & NICOLETTA SACCHI, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," Analytical Biochemistry 162, 156-159 (1987), Copyright 1987 by Academic Press, Inc.

u u u ANN R. KENNEDY, Department of Radiation Oncology, University of PA School of Medicine, Philadelphia, PA 19104, USA, "Chemopreventive Agents: Protease Inhibitors," Pharmacol. Ther. 78(3):167-209, 1998, Copyright 1998 Elsevier Science Inc.

Examiner Signature		Date Considered	11/17/01
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
----------------------	-----------------------	--	----------------

JAMES M. CLARK, WILLIAM M. ABRAHAM, CINDY E. FISHMAN, ROSANNA FORTEZA, ASHFAQ AHMED, ALEJANDRO CORTES, ROBERT L. WARNE, WILLIAM R. MOORE, AND RICHARD D. TANAKA, Dept. of Molecular Pharmacology, Inflammation Program, Arris Pharmaceutical Corp, South San Francisco, CA, and Department of Research, Division of Pulmonary Diseases, University of Miami at Mount Sinai Medical Center, Miami Beach, Florida, "Tryptase Inhibitors Block Allergen-induced Airway and Inflammatory Responses in Allergic Sheep, Am J Respir Crit Care Med Vol 152, pp 2076-2083, 1995

JUSSARA F. MOLINARI, MARIO SCURI, WILLIAM R. MOORE, JAMES CLARK, RICHARD TANAKA, AND WILLIAM M. ABRAHAM, Division of Pulmonary Disease, University of Miami at Mount Sinai Medical Center, Miami Beach, Florida and the Arris Pharmaceutical Corporation, South San Francisco, CA, "Inhaled Tryptase Causes Bronchoconstriction in Sheep Via Histamine Release", am J Respir Crit Care Med Vol 154 pp. 649-653, 1996

Differential Regulation of Human Keratinocyte Growth and Differentiation by a Novel Family of Protease-activated Receptors, Claudia Derian; Cell Growth & Differentiation Vol. 8, 743-749, July 1997

Influence of Nonionic Liposomal Composition on Topical Delivery of Peptide Drugs into Pilosebaceous Units: An in Vivo Study Using the Hamster Ear Model; Pharmaceutical Research, Vol. 12, No. 8, 1995 Pg. 1184-1188

Potent Thrombin Inhibitors That Probe the S1" Subsite; Tripeptide Transition State Analogues Based on a Heterocycle-Activated Carbonyl Group, Journal Medical Chem., 1996, 39, 3039-3043.

~~Chapter 8: Antithrombotics/Serine-Protease; William Ripka and George Vlastik, Covads International, San Diego, CA~~

Cardiovascular and Renal Small molecule direct thrombin inhibitors, Wiley and Fisher, Ashley Publications, Ltd., 1997, pages 1265-1282

~~41USPO2d, Hess v. Advanced Cardiovascular Systems, Inc., Pages 1782-1788~~

~~Helena Rubinstein Whitening with Soybean? HR has launched "Future White" in Japan~~

~~"Isoral" Soybean power makes your skin clear and moist - Brochure~~

~~Elhibin - Brochure~~

Avon's Anew Positivity Trio Targets Menopausal Women, The Rose Sheet, February 28, 2000, page 8

~~Abstract for "Product for Damaged Hair" by Bristol-Myers-Squibb~~

Soybean Technology Improves Skin, Allured's Cosmetics & Toiletries Magazine Vol. 115, No., 3, March 2000, page 22

~~Nudit - Advertisement~~

~~Liposydase, Brochure~~

~~Anti-regrowth effect of hair, pages 11-13~~

Thrombin Inhibitors: Relevant Patent Applications as of 1-Oct-96.

Thrombin Inhibitors: Relevant Patent Applications as of 8 July-98

~~Gastric Juice for antiaging - Abstracts~~

~~Soybeans for skin pigmentation - Abstracts~~

Examiner
Signature

Date
Considered

11/17/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-------------------------	--------------------------	--	----------------

~~Soybeans for skin whitening - Chemical-Substrates~~~~Plant extracts for skin whitening - Abstracts~~~~Abstracts of requested patent titles~~

u "Superscript II Reverse Transcriptase" protocol pub. by Gibco-BRL (now LifeTech Inc) April 1992 *

~~Abstract of JP07304655~~~~Abstract of WO9936050~~~~WO-99/04752 search report~~

u "Evidence for the Presence of a Protease-Activated Receptor Distinct from the Thrombin Receptor in Human Keratinocytes" R.J. Santulli et al. Proceeding of the National Academy of Sciences of USA, vol. 92, Sept 1995, pgs 9151-9155

"Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2" M. Molino et al. Journal of Biological Chemistry, vol. 272, no. 7, 14 Feb 1997 pgs. 4043-4049

U.S. Serial No. 09/361,426 filed July 27, 1999*

Billings et al., Pro. Natl. Acad. Sci. 89:3120-3124 (1992) A Growth-regulated Protease Activity That is Inhibited by the Anticarcinogenic Bowen-Birk Protease Inhibitor.

"The Bowman-Birk Inhibitor", Int. J. Pept. Protein Res. 25:113-131 (1985)*

Kennedy, Am. J. Clin. Nutr. 68:1406S-1412S (1998) The Bowman Birk Inhibitor from Soybeans As An Anticarcinogenic Agent

Liu, K., Chemistry and Nutritional value of soybean components. In: Soybeans, chemistry, technology and utilization. pp. 32-35 (Aspen publishers, Inc., Gaithersburg, MD, 1999)*

Song et al., J. Mol. Biol. 275:347-63 (1998) Kunitz-Type Soybean Trypsin Inhibitor Revisited

"Liposomes—A Selective Drug Delivery System for the Topical Route of Administration; Gel Dosage Form", Journal of Pharmaceutics and Pharmacology, Vol. 34 (1982), pp. 473-474

(EnzChek™ Protease Assay Kits Product Information, Revised 3/15/99; Molecular Probes, Eugene OR)

"Disinfection, sterilization, and preservation" 4th edition, Seymour S. Block, pp. 887-888 (1991, Lea & Febiger, Malvern, PA).

"Official Compendia of Standards, USP 24 USP/NF 19", United States Pharmacopeial Convention, Inc., 2000 (Board of Trustees, United States Pharmacopeial Convention, Inc.)

"Official Methods of Analysis of AOAC International," edited by Patricia Cuniff, Sixteenth Edition, 5th Revision, 1999 (AOAC International)

u A. Meister, Cancer Res. 54:1969s-1975s (1994) Glutathione, Ascorbate, and Cellular Protection

Examiner Signature		Date Considered	1/17/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-------------------------	--------------------------	--	----------------

Current Protocols in Cell Biology, Edited by Juan S. Bonifacino et al. Chapter 6: Electrophoresis and Immunoblotting. Copyright 1999 by John Wiley & Sons, Inc.

D. P. T. Steenvoorden, et al., Photochem Photobiol. 67:651-656 (1998) Protection Against UV-Induced Reactivr Intermediate

Handbook of Non-Invasive Methods and the Skin, eds. J. Serup & G. Jemec, Chapter 14.3 (1995).

Jimenez, M., K., Maloy, WL, and Hearing, V. Specific identification of an authentic tyrosinase clone. J. Biol. Chem. (1989) 264:3397-3403

Jimenez, M., Kameyama, K., Maloy, WL, Tomita Y., and Hearing, V. Mammalian tyrosinase: biosynthesis, processing and modulation by melanocyte stimulating hormone. Proc. Natl. Acad. Sci. USA (1988), 85:3830-34

K. Hanada, et al., J. Invest. Dermatol. 108:727-730 (1997) Photoprotective Effect of Esterified Glutathione Against Ultraviolet B-Induced Sunburn Cell

L. T. van den Broeke and G. M. J. Beijersbergen van Henegouwen, J. Photochem. Photobiol. B Biol. 27:61-65 (1995)

M. J. Connor and L. A. Wheeler, Photochem. Photobiol. 46:239-246 (1987) Depletion of Cutaneous Glutathione By Ultraviolet Radiation

McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986)

Mezei & Gulasekharan, "Liposomes—A Selective Drug Delivery System for the Topical Route of Administration; Gel Dosage Form", Journal of Pharmaceutics and Pharmacology, Vol. 34 (1982), pp. 473-474

Mezei, M., "Liposomes as a Skin Drug Delivery System", Topics in Pharmaceutical Sciences (D. D. Breimer and P. Speiser, eds.), Elsevier Science Publishers B. V., New York, N.Y., 1985, pp. 345-358

R. M. Tyrrell and M. Pidoux, Photochem. Photobiol. 47:405-412 (1988) Correlation Between Endogenous Glutathione

Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972)

Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972)

Stenn, et al., "Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration," 6 Skin Pharmacol. , 125-134 (1993)

Steenvoorden et al., "The Use of Endogenous Antioxidants to Improve Photoprotection" Journal of Photochemistry and Photobiology B: Biology 41 (1997) 1-10.

Chemical Abstracts, Vol. 123, no. 21, 20 November 1995 Columbus, Ohio, US; abstract no. 281641, XP002094580 & R.J. Santulli et al.: "Evidence for the presence of PAR." PROC. NATL. ACAD. SCI USA, vol. 92, no. 20, 1995, page 9151-9155


~~Derwent Abstract of JP.09.025214.A~~

~~Derwent Abstract of JP.04.169514.A~~

~~Derwent Abstract of JP.09.025212.A~~

~~Derwent Abstract of JP.08.099891.A~~

~~Derwent Abstract of JP.08.042560.A~~

Examiner Signature		Date Considered	4/17/01
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 17 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-------------------------	--------------------------	--	----------------

LEUKOCYTOSIS, MONOCYTOSIS AND NEUTROPHILLA; HALLMARKS OF SEVERE DEPRESSION. Maes, M., et al. J. Psychiat. Res. 1992, pp. 125-134

DIAZEPAM INHIBITS PHAGOCYTOSIS AND KILLING EXERTED BY POLYMORPHONUCLEAR CELLS AND MONOCYTES FROM HEALTHY DONORS. Abstract. Immunopharmacology and Immunotoxicology (1989) pp. 701-714

DO MICROGLIAL CELLS PHAGOCYTE THE B/A4-AMYLOID SENILE PLAQUE CORE OF ALZHEIMER DISEASE? Hachimi, K. et al., Academy of Science, Paris. 1994, pp. 445-451

MACROPHAGE UPTAKE OF CHOLESTEROL-CONTAINING PARTICLES DERIVED FROM LDL AND ISOLATED FROM ATHEROSCLEROTIC LESIONS. Hoff, H. F., et al. European Heart Jouenal, 1990, pp. 105-115

CELL-MARIX INTERACTIONS IN THE GENESIS OF ARTERIOSCLEROSIS AND ALATEROMA (Effect of Aging). Robert, L., et al. Laboratoire de Biologie du Tissu Conjonctif 1992, pp. 331-341

ASTROCYTES REGULATE MICROGLIAL PHAGOCYTOSIS OF SENILE PLAQUE CORES OF ALZHEIMER'S DISEASE. DeWitt, David A., Institute of Pathology, 1998 pp. 329-340

PROTEASE-ACTIVATED G PROTEIN COUPLED RECEPTORS ON HUMAN PLATELETS AND ENDOTHELIAL CELLS. Brass, Lawrence F., et al. University of Pennsylvania, 1997, pp. 234-241

PROTEASE ACTIVATED RECEPTORS START A FAMILY. Coughlin, shaun R., University of California, 1994, pp. 9200-9202

MID-DEDERMAL ELASTOLYSIS; AN ULTRASTRUCTURAL AND BIOCHEMICAL STUDY. Fimiani, M., et al., Siena University, 1995, pp. 152-157

NEUTROPHIL AND MONOCYTE PHAGOCYTOSIS IN DEPRESSED PATIENTS. McAdams C., et al. Neuro-Psychopharmacol & Bio. Psychiat, 1998 pp. 971-984

IDENTIFICATION OF POTENTIAL ACTIVATORS OF PROTEINASE-ACTIVATED RECEPTOR-2. Fox, Mark T., et al. Federation of European Biochemical Societies. 1997. Pp. 267-269

ALTERED CELL SIGNALING AND MONONUCLEAR PHAGOCYTE DEACTIVATION DURING INTERACELLULAR INFECTION. Reiner, Neil E. Immunology Today. 1994. Pp. 374-381.


DIFFERENTIAL REGULATION OF HUMAN KERATINOCYTE GROWTH AND DIFFERENTIATION BY A NOVEL FAMLY OF PROTEASE-ACTIVATED RECEPTORS. Darian, Claudia K., et al. Cell Growth & Differentiation. 1997, pp. 743-749

POTENT THROMBIN INHIBITORS THAT PROBE THE S SUBSITE; TRIPEPTIDE TRANSITION STATE ANALOGUES BASED ON A HETEROCYCLE ACTIVATED CARBONYL GRUP. Costanzo, Michael j., et al. J. Med. Chem. 1996, pp. 3039-3043

ADHESION MOLECULE EXPRESSION IN NORMAL SKIN AND MELANOCYTIC LESIONS. Tronnier, Michael, et al. Journal of Cutaneous Pathology, 1997, pp. 278-285

COMMON DISORDERS OF PIGMENTATION. Hacker, Steven M., Postgraduate Medicine. 1996, pp. 177-186

THE ROLE OF NEUTROPHIL ELASTASE IN CHRONIC INFLAMMATION. Doring, Grd. Department of Genreal Hygiene and Environmental Hygiene, 1994, pp. 114-117

Examiner Signature		Date Considered	1/17/01
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 18 of 18

Application Number	09/698,454
Filing Date	October 27, 2000
First Named Inventor	Seiberg, et al.
Group Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	JBP-518

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
-------------------------	--------------------------	--	----------------

INFLAMMATORY AND IMMUNE RESPONSES ARE IMPAIRED IN MICE DEFICIENT IN INTERCELLULAR ADHESION MOLECULE I. Sligh, James E., et al. Proc. Natl. Acad., Sci. 1993, pp. 8529-8533

SUBCELLULAR DISTRIBUTION OF TYROSINASE AND TYROSINASE-RELATED PROTEIN-L; IMPLICATIONS FOR MELANOSOMAL BIOGENESIS. Orlov, Seth J., et al. The Society for Investigative Dermatology, Inc. 1993, pp. 55-64

PHOTOCARCINOGENESIS AND INHIBITION OF INTERCELLULAR ADHESION MOLECULAR I EXPRESSION IN CELLS OF DNA-REPAIR-DEFECTIVE INDIVIDUALS. Ahrens, C., et al. The National Academy of Sciences 1997, pp. 6837-6841

INFLUENCE OF NONIONIC LIPSOMAL COMPOSITION ON TOPICAL DELIVERY OF PEPTIDE DRUGS INTO PILOSEBACEOUS UNITS; AN IN VIVO STUDY USING THE HAMSTER EAR MODEL. Niemiec, S., et al. Pharmaceutical Research, 1995, pp. 1184-1188

INFLAMMATION IN ACNE VULGARIS. Webster, Guy F., Jefferson Medical College. 1995, pp. 247-253

ADHESION MOLECULE EXPRESSION IN NORMAL SKIN AND MELANOCYTIC LESIONS. Tronnier, M., et al. Medical University of Lubeck, Germany. 1996 pp. 278-285

INTECELLULAR ADHESION MOLECULE-1. Van de Stope, A., et al. University Hospital Nijmegen, The Netherlands. 1996 pp. 13-33

~~PERIODONTAL DISEASE, DIABETES, AND IMMUNE RESPONSE; A REVIEW OF CURRENT CONCEPTS. Grant-Therle, D.~~

FLUORESCENCE ASSAY TO MONITOR PHAGOCYTOSIS BY BLOOD-CLOT DERIVED POLYMORPHONUCLEAR LEUCOCYTES STUDY OF PATIENTS WITH DIABETES AND PHAGOCYTOSIS OF DIFFERENT STAPHYLOCOCCAL SPECIES. Muxclow, C. Elizabeth et al., Mount Sinai Hospital, 1991, pp. 15-24

~~REFRACTORY PERIODONTITIS ASSOCIATED WITH ABNORMAL POLYMORPHONUCLEAR LEUKOCYTE PHAGOCYTOSIS AND CIGARETTE SMOKING. MacFarlane, Gordon, et al. University of Minneapolis, pp. 908-913~~

THE ROLE OF PRETEOLYTIC ENZYMES IN THE DEVELOPMENT OF PUMONARY EMPHYSEMA AND PERIODONTAL DISEASE. Travis, J., et al. University of Georgia and Institute of Molecular Biology. 1994, pp. S143-S146

IMMUNOLOGIC ASPECTS OF LUNG DISEASES AND CYSTIC FIBROSIS. Greenberger, Paul A. JAMA, 1997, pp. 1924-1930

Leaflet from Ichimaru Pharcos issued March 7, 1997 "Plant Extract Containing Female Hormone-Like Isoflavones".

~~Abstract of 662255292~~

~~Abstract JP-87256292~~

~~Preservation of Cosmetics, F. Sharpell Chapter 51, p.887-900~~

Partial Purification and Characterization of a Novel Soybean Protease Which is Inhibited by Kunitz and Bowman-Birk Trypsin Inhibitors, Shimpei Morita, Vol. 119, No. 4, 1996 p. 711-718

~~Abstract JP 62036304~~

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

